Instant Case Decision
See if you qualify for Invokana or Other Type II Diabetes Drug litigation and the right to potentially significant financial recovery.
The Invokana Instant Case Evaluator provides lawsuit qualification information and details regarding your situation.
- Did you take Type II diabetes medication?
- Did you then develop ketoacidosis, kindey failure, or another injury?
FDA WARNS – Invokana, Farxiga and Jardiance Linked to Diabetic Ketoacidosis and Kidney Failure
On May 15, 2015 FDA issued a safety warning that the type-2 diabetes mellitus (DM) drugs canagliflozin (Invokana, Johnson & Johnson), dapagliflozin (Farxiga, AstraZeneca plc) and empagliflozin (Jardiance, Boehringer Ingelheim GmbH and Eli Lilly & Company) belonging to SGLT-2 class inhibitors may cause diabetic ketoacidosis, a serious condition that makes blood acidic due to the presence of ketones.
SGLT-2 inhibitors (including Invokana, Farxiga and Jardiance) are a class of FDA approved drugs prescribed for type-2 diabetes patients in conjunction with diet and exercise to lower blood glucose levels. These drugs block glucose reabsorption from the kidney, thus increasing urinary glucose excretion and reducing blood glucose levels.
Diabetic Ketoacidosis is an acute metabolic complication of diabetes, also referred to as diabetic ketoacidosis (DKA). DKA occurs when insulin levels are inadequate to meet the body’s basic metabolic requirements. Insulin deficiency leads to formation of free fatty acids due to breakdown of triglycerides and amino acids, which get converted to highly acidic ketone bodies, leading to acidosis. Symptoms include nausea, vomiting, and abdominal pain that can progress to kidney failure, cerebral edema, coma, and death.
According to the FDA safety alert, patients should stop taking their SGLT2 inhibitor and seek medical attention immediately if they have any symptoms of ketoacidosis, a serious condition in which the body produces high levels of blood acids called ketones.
Symptoms of Diabetic Ketoacidosis
|Trouble Breathing||Rapid Weight Loss|
|Excessive Thirst||Lower stomach or pelvis pain|
|Sweet smell to the breath and/or a sweet metallic taste in the mouth||Signs and symptoms of a urinary tract infection, which includes a feeling of burning when urinating or the need to urinate often or right away|
Latest Invokana News
Should you file an Invokana Lawsuit to protect your legal rights?
Did you use one of these medications?
Did you then develop any of these complications?
Other Kidney Problems
If you answered yes to these two questions you should look into your legal rights. Fill out our Secure Invokana Instant Case Evaluation if you believe you may need to protect your legal rights.
View Your Type II Diabetes Drug Case Analysis Now!
Instant, Secure, No cost/No obligation Analysis of Your Invokana Lawsuit
Invokana Regulatory Action
FDA Approves Invokana
Mar 29, 2013
Initial FDA Alert
May 01, 2014
FDA Warns of Acute Kidney Injury and Impairment in Renal Function
- Mar 2013 - Oct 2014
Life-Threatening Blood Infections
The FDA identified 19 cases of life-threatening blood infections (urosepsis) and kidney infections (pyelonephritis) that started as urinary tract infections with the SGLT2 inhibitors reported to FAERS from March 2013 through October 2014. All 19 patients identified were hospitalized, and a few required admission to an intensive care unit or dialysis in order to treat kidney failure.
- Mar 2013 - May 2015
73 Cases of Ketoacidosis
According to an FDA review of the FDA Adverse Event Reporting System (FAERS) database from March 2013 to May 2015, 73 cases of ketoacidosis in patients with type 1 or type 2 diabetes treated with SGLT2 inhibitors.
- Feb 2016
Recommendations to Minimize the Risk of Diabetic Ketoacidosis
In February 2016, the European Medicines Agency (EMA) confirmed recommendations to minimize the risk of diabetic ketoacidosis in patients taking SGLT2 inhibitors including Invokana, Farxiga and Jardiance. According to the EMA notice, patients taking these medicines need to be aware of the symptoms of diabetic ketoacidosis (DKA) According to Advera Health’s RX Signal, the number of individuals experiencing diabetic ketoacidosis noted by the FDA is understated. According to Advera health, there were 71 cases of DKA from Invokana use and 28 cases of DKA with Farxiga use. These reported numbers are likely to increase as more individuals become aware of the link between SLGT-2 inhibitors and ketoacidosis.